Menu
Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy
Blood and Lymphatic Cancer: Targets and Therapy
- View all (87)
- Volume 12, 2022 (5)
- Volume 11, 2021 (6)
- Volume 10, 2020 (2)
- Volume 9, 2019 (7)
- Volume 8, 2018 (7)
- Volume 7, 2017 (8)
- Volume 6, 2016 (5)
- Volume 5, 2015 (11)
- Volume 4, 2014 (13)
- Volume 3, 2013 (6)
- Volume 2, 2012 (12)
- Volume 1, 2011 (5)
Journal Articles:
- 87 records -
HIV/AIDS Associated Lymphoma: Review
Berhan A, Bayleyegn B, Getaneh Z
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:31-45
Published Date: 29 April 2022
Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma
Kuhlman JJ, Alhaj Moustafa M, Jiang L, Wang J, Gupta V, Tun HW
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:23-29
Published Date: 14 April 2022
Neuropsychiatric Manifestations of Lymphoma-Associated Cerebral Glucose Hypometabolism Can Be Reversed by Intensive Glucose Supplementation
Kase AM, Bullock C, Parrondo R, Alhaj Moustafa M, Iqbal M, Li KD, Parent EE, Tun H
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:17-21
Published Date: 23 March 2022
Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia
Hein K, Short N, Jabbour E, Yilmaz M
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:7-16
Published Date: 19 March 2022
How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice
Guru Murthy GS
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:1-6
Published Date: 19 March 2022
Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission
Seegobin K, Alhaj Moustafa M, Jiang L, Tun HW
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:67-72
Published Date: 22 September 2021
Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
Pongas G, Cheson B
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:55-66
Published Date: 30 July 2021
Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence
Stemer G, Rowe JM, Ofran Y
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:41-54
Published Date: 22 June 2021
Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review
Bender C, Maese L, Carter-Febres M, Verma A
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:25-40
Published Date: 19 April 2021
BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
Gupta VA, Ackley J, Kaufman JL, Boise LH
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:11-24
Published Date: 12 March 2021
The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia – A Single Center Retrospective Study
Liu Q, Major B, Le-Rademacher J, Al-Kali AA, Alkhateeb H, Begna K, Elliott MA, Gangat N, Hogan WJ, Hook CC, Kaufmann SH, Pardanani A, Patnaik MS, Tefferi A, Wolanskyj-Spinner AP, Wei W, Litzow MR
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:1-9
Published Date: 22 January 2021
Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
Sigmund AM, Sahasrabudhe KD, Bhatnagar B
Blood and Lymphatic Cancer: Targets and Therapy 2020, 10:7-20
Published Date: 3 November 2020
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
Ujjani C, Mato A, Hill BT, Allan JN, Lansigan E, Jacobs R, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M
Blood and Lymphatic Cancer: Targets and Therapy 2020, 10:1-5
Published Date: 24 August 2020
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Lai C, Kandahari AM, Ujjani C
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:63-71
Published Date: 9 December 2019
Knockout Of BIRC5 Gene By CRISPR/Cas9 Induces Apoptosis And Inhibits Cell Proliferation In Leukemic Cell Lines, HL60 And KG1
Narimani M, Sharifi M, Jalili A
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:53-61
Published Date: 27 November 2019
Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
Carrà G, Cartellà A, Maffeo B, Morotti A
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:45-52
Published Date: 6 November 2019
Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
Zhang F, Li L, Zhang L, Li X, Fu X, Wang X, Wu J, Sun Z, Kong F, Ren L, Zhang M
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:33-43
Published Date: 19 August 2019
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
Megías-Vericat JE, Ballesta-López O, Barragán E, Montesinos P
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:19-32
Published Date: 27 June 2019
The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
Schieber M, Ma S
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:9-17
Published Date: 12 March 2019
Strategies for minimal residual disease detection: current perspectives
Andreani G, Cilloni D
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:1-8
Published Date: 12 February 2019
Plasmablastic lymphoma: current perspectives
Lopez A, Abrisqueta P
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:63-70
Published Date: 4 October 2018
Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
Hefazi M, Litzow MR
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:47-61
Published Date: 25 September 2018
Current understanding of the role and regulation of miRNAs in Burkitt lymphoma
Videtta AD, Malagnino V, De Falco G
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:33-45
Published Date: 11 May 2018
Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
Blum A, Bazou D, O'Gorman P
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:21-31
Published Date: 20 April 2018
Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
Lapuz C, Enjeti AK, O'Brien PC, Capp AL, Holliday EG, Gupta SA
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:13-20
Published Date: 18 April 2018
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]
Anagnostou T, Litzow MR
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:11-12
Published Date: 11 April 2018
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
Anagnostou T, Litzow MR
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:1-9
Published Date: 22 December 2017
Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects
Trottier AM, Cerquozzi S, Owen CJ
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:85-93
Published Date: 11 December 2017
Impact of obinutuzumab alone and in combination for follicular lymphoma
Sarraf Yazdy M, Cheson BD
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:73-83
Published Date: 19 October 2017
Complications and management of coagulation disorders in leukemia patients
Lad DP, Jain A, Varma S
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:61-72
Published Date: 18 September 2017
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
Bhutani D, Zonder JA
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:53-60
Published Date: 19 July 2017
Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
Karantanos T, Politikos I, Boussiotis VA
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:37-52
Published Date: 9 May 2017
Clinical potential of midostaurin in advanced systemic mastocytosis
Chandesris MO, Damaj G, Lortholary O, Hermine O
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:25-35
Published Date: 3 May 2017
Uptake of lymphoma-derived exosomes by peripheral blood leukocytes
Ferguson Bennit HR, Gonda A, Oppegard LJ, Chi DP, Khan S, Wall NR
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:9-23
Published Date: 28 February 2017
Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
Oncale MB, Maymani H, Nastoupil LJ
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:1-7
Published Date: 16 February 2017
Waldenström macroglobulinemia: biology, genetics, and therapy
Paludo J, Ansell SM
Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:49-58
Published Date: 26 July 2016
Managing treatment-related peripheral neuropathy in patients with multiple myeloma
Grammatico S, Cesini L, Petrucci MT
Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:37-47
Published Date: 29 June 2016
Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes
Faiman B, Valent J
Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:21-35
Published Date: 24 May 2016
Ruxolitinib: a targeted treatment option for patients with polycythemia vera
Vaddi K, Verstovsek S, Kiladjian JJ
Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:7-19
Published Date: 12 May 2016
Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
Madanat YF, Smith MR, Almasan A, Hill BT
Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:1-6
Published Date: 15 March 2016
Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
Bodiford A, Talbott MS, Reddy NM
Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:109-114
Published Date: 11 September 2015
Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose
Waclaw J, Sacha T, Stoklosa T
Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:101-108
Published Date: 9 September 2015
Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment
Pujals A, Favre L, Gaulard P, Wiels J
Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:93-100
Published Date: 29 July 2015
MYC as therapeutic target in leukemia and lymphoma
Cortiguera MG, Batlle-López A, Albajar M, Delgado MD, León J
Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:75-91
Published Date: 22 July 2015
The expanding role of bendamustine in chronic lymphocytic leukemia
Nair KS, Ujjani C
Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:65-74
Published Date: 8 July 2015
IL-15 as a potential target in leukemia
Xiong Y, Bensoussan D, Decot V
Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:55-63
Published Date: 9 April 2015
Targeting CD20 in chronic lymphocytic leukemia
Nahas MR, Arnason JE
Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:43-53
Published Date: 10 March 2015
Emerging role of SOX11 in mantle cell lymphoma
Kuci V, Nordström L, Jerkeman M, Ek S
Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:35-42
Published Date: 27 February 2015
MicroRNAs as B-cell lymphoma biomarkers
Manterola L, Fernandez-Mercado M, Larrea E, Goicoechea I, Arestin M, Armesto M, Hernandez L, Lawrie CH
Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:25-34
Published Date: 4 February 2015
Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma
Yoshimitsu M, Arima N
Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:17-23
Published Date: 18 December 2014
Preserving fertility in young patients with lymphoma: an overview
Patel B, Rossi BV
Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:1-15
Published Date: 18 December 2014
Multiple myeloma: optimal management and long-term disease control
Sriskandarajah P, Davies FE
Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:121-134
Published Date: 6 November 2014
B-cell malignancies: capture-sequencing strategies for identification of gene rearrangements and translocations into immunoglobulin gene loci
Boyle EM, Walker BA, Wardell CP, Leleu X, Davies FE, Morgan GJ
Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:107-119
Published Date: 30 October 2014
Coexistence of primary myelofibrosis and chronic lymphocytic leukemia
Burgstaller S, Thaler J
Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:101-105
Published Date: 3 October 2014
Optimal management of endemic Burkitt lymphoma: a holistic approach mindful of limited resources
Moormann AM, Skiles JL, Otieno JA, Buckle GC, Vik TA
Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:91-99
Published Date: 23 September 2014
Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib
Shoumariyeh K, von Bubnoff N
Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:81-89
Published Date: 18 September 2014
Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
Farina F, Stasia A, Gambacorti-Passerini C
Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:69-79
Published Date: 21 August 2014
Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
Harnicar S, Mathew S
Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:61-67
Published Date: 21 August 2014
Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
McKinney MS, Beaven AW
Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:45-59
Published Date: 16 August 2014
The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use
Kaufman GP, Ristow KM, Markovic SN, Porrata LF
Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:39-44
Published Date: 23 July 2014
Splenic marginal zone lymphoma: a review of the clinical presentation, pathology, molecular biology, and management
Teixeira Mendes LS, Du MQ, Matutes E, Wotherspoon A
Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:29-38
Published Date: 17 July 2014
Profile of elotuzumab and its potential in the treatment of multiple myeloma
Liu YC, Szmania S, van Rhee F
Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:15-27
Published Date: 3 June 2014
Treating the elderly patient with chronic lymphocytic leukemia: current and emerging options
Mozaheb Z
Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:9-14
Published Date: 19 May 2014
Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
Thomas X
Blood and Lymphatic Cancer: Targets and Therapy 2014, 4:1-8
Published Date: 17 April 2014
Emerging targets in human lymphoma: targeting the MYD88 mutation
Wang JQ, Jeelall YS, Horikawa K
Blood and Lymphatic Cancer: Targets and Therapy 2013, 3:53-61
Published Date: 13 August 2013
Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
Gupta VA, Nooka AK, Lonial S, Boise LH
Blood and Lymphatic Cancer: Targets and Therapy 2013, 3:41-51
Published Date: 16 May 2013
MicroRNA dysregulation in B-cell non-Hodgkin lymphoma
Lim EL, Marra MA
Blood and Lymphatic Cancer: Targets and Therapy 2013, 3:25-40
Published Date: 8 May 2013
Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies
Gopalakrishnan S, Tan D
Blood and Lymphatic Cancer: Targets and Therapy 2013, 3:19-24
Published Date: 18 April 2013
Ruxolitinib as an emerging treatment in myelofibrosis
Emanuel RM, Geyer HL, Mesa RA
Blood and Lymphatic Cancer: Targets and Therapy 2013, 3:11-18
Published Date: 9 March 2013
Novel conditioning regimens for bone marrow transplantation
Shi M, Li M, Ikehara S
Blood and Lymphatic Cancer: Targets and Therapy 2013, 3:1-9
Published Date: 8 January 2013
Therapeutic developments in acute lymphoblastic leukemia
MacKenzie A, Kasner M
Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:145-158
Published Date: 27 November 2012
Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia
Borthakur G, O'Brien S
Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:137-143
Published Date: 20 August 2012
Recent developments in myelofibrosis
Tibes R, Bogenberger JM, Mesa RA
Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:125-136
Published Date: 2 July 2012
Role of L-asparaginase in acute lymphoblastic leukemia: focus on adult patients
Rytting ME
Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:117-124
Published Date: 29 June 2012
Peripheral T cell lymphoma: clinical utility of romidepsin
Zain J, Sawey K
Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:109-115
Published Date: 13 June 2012
Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
Mayes S, Gibb A, Illidge T
Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:99-107
Published Date: 21 May 2012
Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future
Sinha R, Nastoupil LJ, Flowers CR
Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:87-98
Published Date: 19 April 2012
First-line therapy of chronic myeloid leukemia – focus on dasatinib
Amrein PC
Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:77-85
Published Date: 24 April 2012
Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias
Thomas X
Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:57-76
Published Date: 5 March 2012
Advances in the diagnosis and management of lymphoma
Word ZH, Matasar MJ
Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:29-55
Published Date: 3 February 2012
Trends in the treatment of cutaneous T-cell lymphoma – critical evaluation and perspectives on vorinostat
Rangwala S, Duvic M, Zhang CL
Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:17-27
Published Date: 1 February 2012
The evaluation and optimal use of rituximab in lymphoid malignancies
Robak T, Robak P, Smolewski P
Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:1-16
Published Date: 4 January 2012
Reduced intensity treatment in early-stage Hodgkin’s lymphoma
Prodduturi P, Armitage JO
Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:23-31
Published Date: 25 November 2011
mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report
Ibeas P, Cantos B, Provencio M.
Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:19-22
Published Date: 8 November 2011
Leptomeningeal myelomatosis in previously treated high-risk kappa light chain multiple myeloma: case report and literature review
Ohanian M, Alaly J, Samuel S, Cable C, Halka K
Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:9-18
Published Date: 28 September 2011
Mantle cell leukemia as a cause of leukostasis
Smith D, Cable C, Chisholm C, Linz W, Koss W, Dobin S, Rappaport E
Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:5-8
Published Date: 28 April 2011
A new era in blood and lymphatic cancer biology and therapy
David Dingli
Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:1-3
Published Date: 8 March 2011